Another data cut from Ultragenyx Pharmaceutical Inc. regarding UX-111 (rebisufligene etisparvovec), an AAV9 gene therapy for type A Sanfilippo syndrome, continued to brighten the picture for the compound, recently taken under review again by the U.S. FDA.
Nearly three months after winning a contentious bid to buy obesity drugmaker Metsera Inc. for $10 billion, Pfizer Inc. reported its first statistically significant top-line data of the acquired lead, ultra-long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, showing a mean placebo-adjusted weight loss of up to 12.3% at 28 weeks, as well as competitive tolerability.
Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did not disclose specifics around the licensed candidate, except that it was derived from its LEAD (Ligand and Enhancer Assisted Delivery) platform.
Amgen Inc. quit a development deal with Kyowa Kirin Co. Ltd., returning global rights for rocatinlimab, Kyowa Kirin’s T-cell rebalancing therapy being investigated for moderate to severe atopic dermatitis.
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Chiesi, Eli Lilly, Johnson & Johnson, Protalix, Sanofi, Ultragenyx, Unicycive.
Biopharma happenings, including deals and partnerships, and other news in brief: Alps, Amgen, Astrazeneca, Bayer, IO Biotech, Kyowa, Moderna, Poxel, Recordati, Regeneron, Samsung Bioepsis.
RSS
.webp?height=488&t=1750428815&width=650 "Interfering RNA (RNAi)")